EA200900806A1 - Способы увеличения количества и мобилизации гемопоэтических стволовых клеток - Google Patents

Способы увеличения количества и мобилизации гемопоэтических стволовых клеток

Info

Publication number
EA200900806A1
EA200900806A1 EA200900806A EA200900806A EA200900806A1 EA 200900806 A1 EA200900806 A1 EA 200900806A1 EA 200900806 A EA200900806 A EA 200900806A EA 200900806 A EA200900806 A EA 200900806A EA 200900806 A1 EA200900806 A1 EA 200900806A1
Authority
EA
Eurasian Patent Office
Prior art keywords
increasing
stem cells
mobilization
methods
hemopoetic
Prior art date
Application number
EA200900806A
Other languages
English (en)
Other versions
EA018983B1 (ru
Inventor
Александр Шахов
Евгения Стром
Original Assignee
Кливлэнд Биолабс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кливлэнд Биолабс, Инк. filed Critical Кливлэнд Биолабс, Инк.
Publication of EA200900806A1 publication Critical patent/EA200900806A1/ru
Publication of EA018983B1 publication Critical patent/EA018983B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Abstract

Предложен способ увеличения числа гемопоэтических стволовых клеток в костном мозге, увеличения мобилизации этих клеток из костного мозга в кровоток и в другие ткани, а также увеличения числа дифференцирующихся гемопоэтических стволовых клеток в кровотоке.
EA200900806A 2007-01-09 2008-01-09 Способ усиления миграции гемопоэтических стволовых клеток, способ получения популяции указанных клеток и способы лечения с их использованием EA018983B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88416207P 2007-01-09 2007-01-09
US88989307P 2007-02-14 2007-02-14
US93856407P 2007-05-17 2007-05-17
US1324307P 2007-12-12 2007-12-12
PCT/US2008/050644 WO2008086426A2 (en) 2007-01-09 2008-01-09 Methods for increasing and mobilizing hematopoietic stem cells

Publications (2)

Publication Number Publication Date
EA200900806A1 true EA200900806A1 (ru) 2010-08-30
EA018983B1 EA018983B1 (ru) 2013-12-30

Family

ID=39609361

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900806A EA018983B1 (ru) 2007-01-09 2008-01-09 Способ усиления миграции гемопоэтических стволовых клеток, способ получения популяции указанных клеток и способы лечения с их использованием

Country Status (15)

Country Link
US (3) US20100055077A1 (ru)
EP (1) EP2115124B1 (ru)
JP (1) JP5389666B2 (ru)
KR (1) KR101493474B1 (ru)
CN (1) CN101631850B (ru)
BR (1) BRPI0806557A2 (ru)
CA (1) CA2675032A1 (ru)
EA (1) EA018983B1 (ru)
HK (1) HK1134835A1 (ru)
IL (1) IL199766A (ru)
MX (1) MX2009007391A (ru)
NZ (2) NZ603805A (ru)
SG (1) SG177959A1 (ru)
WO (1) WO2008086426A2 (ru)
ZA (1) ZA200905378B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539490T3 (es) 2005-06-13 2015-07-01 Cleveland Biolabs, Inc. Métodos para proteger frente a apoptosis usando lipopéptidos
ES2444695T3 (es) * 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
WO2011053700A1 (en) * 2009-10-28 2011-05-05 Henry Ford Health System Methods to mitigate injury from radiation exposure
EP2338521A1 (en) * 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
US20130230580A1 (en) * 2010-09-14 2013-09-05 Paul S. Frenette Administration of SNS Neuroprotective Agents to Promote Hematopoietic Regeneration
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
ES2731665T3 (es) 2012-01-09 2019-11-18 Adc Therapeutics Sa Agentes para tratar cáncer de mama triple negativo
WO2013149064A1 (en) * 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
WO2013159082A1 (en) 2012-04-20 2013-10-24 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
JP2016518415A (ja) * 2013-10-21 2016-06-23 アドバンスド ニューロリジェネレイティブ セラピーズ エルエルシー 加齢と疾患免疫機能障害と細胞老化とをリンパ球系幹細胞で修復する方法、及び治療使用のためのそれらの再適用する方法
CN104744563B (zh) * 2013-12-27 2019-02-26 中国人民解放军军事医学科学院毒物药物研究所 端基具有亲脂性结构的线性脂肽、其制备方法及用途
WO2016073733A1 (en) * 2014-11-06 2016-05-12 Cleveland Biolabs, Inc. Methods of treating cancer using lipopeptides
US20210189344A1 (en) * 2018-08-30 2021-06-24 The Regents Of The University Of California Mobilization and collection of peripheral blood hematopoietic stem cells from deceased donors
CN112851755B (zh) * 2021-01-13 2023-09-01 中国人民解放军军事科学院军事医学研究院 一种线性脂肽化合物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
DE19822820A1 (de) * 1998-05-20 1999-11-25 Biotechnolog Forschung Gmbh Pharmazeutisches Präparat zur Wundbehandlung
ES2539490T3 (es) * 2005-06-13 2015-07-01 Cleveland Biolabs, Inc. Métodos para proteger frente a apoptosis usando lipopéptidos
RU2009108289A (ru) * 2006-08-07 2010-09-20 Джензим Корпорейшн (Us) Комбинированная терапия

Also Published As

Publication number Publication date
US20100055077A1 (en) 2010-03-04
ZA200905378B (en) 2010-05-26
WO2008086426A8 (en) 2009-07-30
EP2115124A4 (en) 2012-05-30
SG177959A1 (en) 2012-02-28
US20150174195A1 (en) 2015-06-25
HK1134835A1 (en) 2010-05-14
NZ578928A (en) 2013-03-28
WO2008086426A2 (en) 2008-07-17
MX2009007391A (es) 2009-08-13
NZ603805A (en) 2014-03-28
AU2008204836A1 (en) 2008-07-17
EP2115124A2 (en) 2009-11-11
KR20090108703A (ko) 2009-10-16
IL199766A (en) 2015-01-29
BRPI0806557A2 (pt) 2014-04-15
KR101493474B1 (ko) 2015-02-16
JP5389666B2 (ja) 2014-01-15
EA018983B1 (ru) 2013-12-30
US20140045747A1 (en) 2014-02-13
JP2010515748A (ja) 2010-05-13
CN101631850B (zh) 2013-12-04
CA2675032A1 (en) 2008-07-17
CN101631850A (zh) 2010-01-20
EP2115124B1 (en) 2016-03-16
WO2008086426A3 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
EA200900806A1 (ru) Способы увеличения количества и мобилизации гемопоэтических стволовых клеток
WO2008051568A3 (en) Methods and compositions for treatment of bone defects with placental cell populations
WO2008064116A3 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
EA201300116A1 (ru) Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
EA200602099A1 (ru) Получение прегабалина и родственных соединений
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
BRPI1013771A2 (pt) "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."
ATE480615T1 (de) Verfahren zur proliferation von stammzellen
MX2009014273A (es) Metodos y composiciones para expansion e implantacion optimizadas de celulas madre mesenquimales.
WO2010059565A3 (en) Allografts combined with tissue derived stem cells for bone healing
EA200801560A1 (ru) Бифенилкарбоксамиды
EA201270350A1 (ru) Способ идентификации и получения (r)-специфической омега-трансаминазы
MY159971A (en) Multipotent/pluripotent cells and methods
WO2008130989A3 (en) Prosthetic implants
SG166770A1 (en) Use of adipose tissue-derived stromal stem cells in treating fistula
WO2006050330A3 (en) Platelets from stem cells
WO2012006100A3 (en) Methods and compositions for enhancing stem cell mobilization
WO2007041546A3 (en) Method for selectively depleting hypoxic cells
WO2007136424A3 (en) Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
WO2008058233A3 (en) In vivo bioreactors and methods of making and using same
EA201290513A1 (ru) Новые производные (гетероциклотетрагидропиридин)-(пиперазинил)-1-алканона и (гетероциклодигидропирролидин)-(пиперазинил)-1-алканона и их применение в качестве ингибиторов р75
WO2010137021A3 (en) Method of generating connective tissue
RU2010137504A (ru) Способ ароматизации табака
ATE496118T1 (de) Verfahren zur herstellung differenzierter hämatopoetischer zellen zur behandlung von zytopenie

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU